Oral 4: SVR12 (sustained virologic response 12 weeks post-treatment) of 99% Achieved With a Ribavirin-Free Regiment

Andreas Maieron, MD
Andreas Maieron, MD

Author Insight from Andreas Maieron, MD, Elisabeth Hospital, Linz, Austria

What’s new here and important for clinicians?

Oral 4
Oral 4

The 3D regime consisting of protease inhibitor ABT-450 and ritonavir co-formulated with the NS5A inhibitor ombitasvir (ABT-267), as well the non-nucleoside polymerase inhibitor dasabuvir (ABT-333) has shown extremely high SVR rates among GT 1b patients. It is notable that these results can be obtained irrespective of previous IFN based therapy and more over treatment response and other baseline factors like IL28, sex, age, race, BMI, fibrosis stage, viral load. GT 1b patients do not need Ribavirin to achieve these SVR rates of 99%.

What do patients need to know?
The 3 D regimes offers a safe and good tolerable treatment option with very favourable cure rates of 99% in GT 1b infected individuals. Less than 1% discontinued treatment due to adverse events. This is a save and highly effective treatment.


Read the Abstract

Author Contact

Andreas Maieron, MD, Elisabeth Hospital, Linz, Austria


Related Abstracts

Oral 5 Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT -450/R/Ombitasvir, Dasabuvir and Ribavirin

To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.